Sarcomatoid Renal Cell Carcinoma: An Immune Checkpoint-responsive Subset?

Affiliations

¹ Department of Biostatistics and Bioinformatics; Duke Cancer Institute Center. Electronic address: susan.halabi@duke.edu.
² Duke Cancer Institute Center for Prostate and Urologic Cancers.

Editorial

Susan Halabi et al. Eur Urol. 2021 May.

. 2021 May;79(5):663-664.

doi: 10.1016/j.eururo.2021.01.042. Epub 2021 Feb 13.

¹ Department of Biostatistics and Bioinformatics; Duke Cancer Institute Center. Electronic address: susan.halabi@duke.edu.
² Duke Cancer Institute Center for Prostate and Urologic Cancers.

No abstract available

Comment on

Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial.
Rini BI, Motzer RJ, Powles T, McDermott DF, Escudier B, Donskov F, Hawkins R, Bracarda S, Bedke J, De Giorgi U, Porta C, Ravaud A, Parnis F, Grande E, Zhang W, Huseni M, Carroll S, Sufan R, Schiff C, Atkins MB. Rini BI, et al. Eur Urol. 2021 May;79(5):659-662. doi: 10.1016/j.eururo.2020.06.021. Epub 2020 Jul 9. Eur Urol. 2021. PMID: 32654802 Free PMC article.